Kabra Drugs Ltd (524322)
🎯 Key Takeaways
- Kabra Drugs Ltd appears to be in a phase of administrative restructuring and governance refinement rather than operational expansion or financial recovery. The company has no promoter holding, negligible institutional ownership, and operates in a highly fragmented public shareholder base.
- Revenue grew 30.5% QoQ to ₹46 in Q1FY27.
- ⚠️ 1) The company operates with no promoter stake and minimal institutional ownership, which may lead to lower governance scrutiny and liquidity challeng
- Market Cap
- ₹49
- P/E Ratio
- 6.5
- P/B Ratio
- 1.66
- ROE
- 25.6%
- ROCE
- 30.1%
- Debt/Equity
- 0.02
- Promoter
- 0.0%
📖 The Story
Kabra Drugs Ltd appears to be in a phase of administrative restructuring and governance refinement rather than operational expansion or financial recovery. The company has no promoter holding, negligible institutional ownership, and operates in a highly fragmented public shareholder base. Despite historically volatile profitability, recent quarters show modest revenue growth and improving margins, though profitability remains sensitive to scale and operational efficiency.
📰 What's Happening
The company recently completed a change in its registered office from Indore to Chennai, effective August 28, 2026, following board and regulatory approvals, as disclosed in a BSE filing on August 29, 2026. This move is purely administrative and does not affect operations or financials. Additionally, a board meeting is scheduled for September 2, 2026, to approve the Director's Report, finalize AGM dates, re-appoint a retiring director, and recommend new director and secretarial auditor appointments, as per a filing dated August 27, 2026. These actions reflect routine governance updates rather than strategic shifts.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 7 | 20 | 30 | 35 | 46 |
| Operating Profit | -1 | 2 | 2 | 1 | 3 |
| OPM % | -7.3% | 10.3% | 8.0% | 3.7% | 6.0% |
| Net Profit | -1 | 2 | 3 | 1 | 2 |
| EPS | ₹-0.21 | ₹0.77 | ₹1.08 | ₹0.45 | ₹0.90 |
The company has demonstrated a clear upward trend in revenue and profitability over the past year, with June 2026 revenue at ₹46 crore and operating profit of ₹3 crore (6% margin), up from ₹20 crore revenue and 10.3% OPM in September 2025. Profitability dipped in early 2025 due to losses but has since stabilized, with net profit rising to ₹2 crore in June 2026 from ₹1 crore in March 2026. However, margins remain volatile, and the company posted a loss in Q1 FY26 (June 2025), indicating sensitivity to operational scaling and cost management.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue, margins, or growth targets in the available filings. The focus appears to be on governance and administrative matters rather than strategic outlook. No commentary on future business expansion, product launches, or market expectations was found in the reviewed disclosures.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 24 | 10 | 24 | 24 |
| Reserves | 1 | -7 | 6 | 2 |
| Borrowings | 0 | 1 | 1 | 0 |
| Total Liabilities | 25 | 5 | 86 | 55 |
| Fixed Assets | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 1 |
| Total Assets | 25 | 5 | 86 | 55 |
The balance sheet shows a strong equity base of ₹24 crore with minimal debt (₹1 crore borrowings as of March 2026), and total assets have grown from ₹25 crore in March 2025 to ₹86 crore in March 2026, suggesting asset buildup. Reserves increased from ₹1 crore to ₹6 crore over the same period, indicating retained earnings or revaluation. The capital structure remains conservative with negligible leverage, supporting financial stability but limiting growth agility through debt financing.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -5 |
| Investing | -0 |
| Financing | +23 |
| Net Cash Flow | +19 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 95.0% | 91.4% | 90.9% | 90.7% |
| # Shareholders | 8,098 | 8,862 | 9,185 | 9,680 |
Promoter holding remains at 0%, with public shareholding declining slightly from 95% in Q2 FY26 to 90.69% in Q1 FY27, while the number of public shareholders has increased from 8,098 to 9,680. There has been no FII or DII holding reported in any of the recent quarters, suggesting limited institutional interest or visibility. The growing number of small public shareholders may reflect retail participation but lacks concentration or voting influence.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) The company operates with no promoter stake and minimal institutional ownership, which may lead to lower governance scrutiny and liquidity challenges. 2) Profitability remains volatile, as evidenced by losses in Q1 FY26 and fluctuating operating margins, raising concerns about sustainable earnings quality. 3) The business scale appears small and concentrated, with revenue growing from ₹7 crore to ₹46 crore over a year but still vulnerable to demand or pricing shifts. 4) Lack of forward guidance from management introduces uncertainty around future performance and strategic direction.
📋 Recent Filings
- 🟡 Board Meeting2026-09-30Aanjaay Industries Limited held its 37th AGM on 30 September 2026 at Fairfield by Marriott Hotel, Chennai, where shareholders approved the adoption of…
- Announcement2026-09-28Kabra Drugs Ltd announced that its trading window will close on 1 October 2026 for all designated persons and their relatives until 48 hours after the…
- 🔴 annual report2026-09-08Aanjaay Industries Limited (formerly Kabra Drugs Limited) filed its 2025-26 Annual Report with BSE on September 8, 2026, announcing the 37th Annual Ge…
- 🟡 Board Meeting2026-09-07Aanjaay Industries Limited (formerly Kabra Drugs Ltd) announced its 37th Annual General Meeting on 30 September 2026 at 09:00 AM in Chennai. Sharehold…
- 🟡 voting results2026-09-03Kabra Drugs Ltd announced book closure from September 24 to 30, 2026, for its proposed AGM on September 30, 2026, with e-voting events scheduled betwe…
- 🟡 Board Meeting2026-09-02Kabra Drugs Ltd appointed Mrs. Twinkle Agarwal as Secretarial Auditor for FY 2026-2027 to 2027-2031 following its September 2, 2026 board meeting, to …
- 🟡 Board Meeting2026-09-02Kabra Drugs Ltd appointed Karthik L & Associates as its internal auditor for FY 2026-27, effective September 2, 2026, to meet SEBI LODR compliance req…
- 🟡 Board Meeting2026-09-02The board approved the Director's Report and Corporate Governance Report for FY2026, closed share transfer books from September 24-30, 2026, set Septe…
- 🟡 Board Meeting2026-08-29Kabra Drugs Ltd announced a change in its registered office from Indore, Madhya Pradesh to Chennai, Tamil Nadu, effective August 28, 2026, following b…
- 🟡 Board Meeting2026-08-27Kabra Drugs Ltd announced a board meeting on September 2, 2026, to approve the Director's Report, close shareholder records for its AGM, fix voting da…
🧠 Analyst's Read
Kabra Drugs Ltd is undergoing quiet governance and structural changes without clear signals of operational acceleration or market expansion. While recent financial trends show improvement in revenue and margins, the business remains small, marginally profitable, and lacks institutional conviction. Investors should monitor upcoming AGM outcomes and any future commentary on growth strategy or margin improvement initiatives for early signals of management's long-term intent.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day